ArticleMaterials (Basel, Switzerland)2018
Hydrophilic and Hydrophobic Mesoporous Silica Derived from Rice Husk Ash as a Potential Drug Carrier.
Article in Materials (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 16 citations in OpenAlex.
- Agricultural and Agro-Industrial Residues as Sustainable Sources of Next-Generation Biomedical Materials: Advances, Challenges, and Perspectives.Life (Basel, Switzerland) · 2025Review
- Encapsulation of Ibuprofen by Pickering-Stabilized Antibubbles.ACS omega · 2025Article
- Sugarcane ash and sugarcane ash-derived silica nanoparticles alter cellular metabolism in human proximal tubular kidney cells.Environmental pollution (Barking, Essex : 1987) · 2023Article
- A comparative study of femtosecond pulsed laser ablation of meloxicam in distilled water and in air.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This work describes the preparation of mesoporous silica by the green reaction of rice husk ash (RHA) with glycerol, followed by the modification and the potential use as a drug carrier. The reaction was carried out at 215 °C for 2 h. The solution was further hydrolyzed with deionized water and aged for various times (24, 48, 120, 360, 528 and 672 h) before calcinations at 500 °C for 24 h. Further treatment of prepared mesoporous silica was performed using trimethylmethoxysilane (TMMS) to obtain hydrophobic Mesoporous silica. For all synthesized silicas, silica contents were as high as 95 wt %, whereas organic residues were less than 3 wt %. RHA-glycerol showed the highest specific surface area with smallest pore diameter (205.70 m²/g, 7.46 nm) when aged for 48 h. The optimal hydrolysis-ageing period of 120 h resulted in 500.7 m²/g specific surface area, 0.655 cm³/g pore volume and 5.23 nm pore diameter. The surface modification of RHA-glycerol occurred through the reaction with TMMS as confirmed by FTIR (Fourier-transform infrared spectroscopy). Ibuprofen was selected as a model drug for the adsorption experiments. The adsorption under supercritical CO₂ was carried out at isothermal temperature of 40 °C and 100 bar; % ibuprofen loading of TMMS modified mesoporous silica (TMMS-g-MS) was 6 times less than that of mesoporous silica aged for 24 h (MS-24h) due to the hydrophobic nature of modified mesoporous silica, not surface and pore characteristics. The release kinetics of ibuprofen-loaded mesoporous silicas were also investigated in vitro. The release rate of ibuprofen-loaded MS-24h was much faster than that of ibuprofen-loaded TMMS-g-MS, but comparable to the crystalline ibuprofen. The slower release rate was attributed to the diffusion control and the stability of hydrophobic nature of modified silica. This would allow the design of a controlled release drug delivery system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.